Nanobody for Alzheimer's disease moves closer toward phase I clinical trial

Ablynx to receive €1 million milestone payment

26-Apr-2012 - Belgium

Ablynx announced that Boehringer Ingelheim has submitted a Clinical Trials Application (CTA)  to the European regulatory authorities to start a Phase I clinical trial with a Nanobody® for the treatment of Alzheimer's disease. The Nanobody has been developed as part of the collaboration signed between Ablynx and Boehringer and the event triggers a €1 million milestone payment to Ablynx.

In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies against a single disease target. The collaboration has a potential value of $265 million in upfront and milestone payments plus undisclosed royalties on product sales. Boehringer Ingelheim is solely responsible for the development, manufacturing and commercialisation of any products resulting from the collaboration.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances